Psilocybin is a Schedule 1 Prohibited Substance in most parts of the world, but various jurisdictions are enabling access to psilocybin by one (or both) of two pathways: decriminalisation and legalisation. This talk will provide an overview of the current legal status and models of access to psilocybin in various countries, and the way forward in medical and non-clinical contexts.
Martin Williams, PhD is a Senior Research Fellow at the Centre for Mental Health, Swinburne University. Martin’s research background is in Medicinal Chemistry and Pharmacology, and he is Executive Director of Psychedelic Research in Science & Medicine (PRISM) and Vice-President of Entheogenesis Australis (EGA). Martin has been a co-investigator on a number of Australian clinical trials of psychedelic-assisted psychotherapy, including the St Vincent’s Hospital Melbourne study of psilocybin-assisted psychotherapy in palliative care; the Monash PsiConnect neuroimaging study of psilocybin with mindfulness meditation; the Swinburne PsiloDep pilot study; and several other studies of psilocybin, MDMA and other psychedelics for the treatment of a range of mental health conditions.
Entheogenesis Australis (EGA) is a charity using education to help grow the Australian ethnobotanical community and their gardens. We encourage knowledge-sharing on botanical research, conservation, medicinal plants, arts, and culture.
